Satellos doses first DMD subject in Phase Ib trial

Satellos Bioscience has dosed the first subject with Duchenne muscular dystrophy (DMD) in a Phase Ib trial of its oral small molecule drug candidate, SAT-3247.

The study aims to evaluate the pharmacokinetics (PK) of the therapy in up to ten adult subjects with genetically confirmed DMD over 28 days.